Rhonda Farnum Sells 4,000 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at $2,904,687. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Theravance Biopharma Stock Up 8.6 %

Theravance Biopharma stock traded up $0.77 during midday trading on Wednesday, reaching $9.68. The company’s stock had a trading volume of 285,946 shares, compared to its average volume of 346,350. The business has a 50-day simple moving average of $8.32 and a 200-day simple moving average of $8.68. Theravance Biopharma, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $11.71. The company has a market cap of $473.56 million, a P/E ratio of -9.92 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.23% and a negative net margin of 78.18%. The business had revenue of $16.87 million for the quarter, compared to analyst estimates of $16.11 million. During the same quarter in the previous year, the firm posted ($0.17) EPS. As a group, equities analysts forecast that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current year.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of TBPH. Quantbot Technologies LP bought a new stake in Theravance Biopharma during the third quarter worth approximately $60,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Theravance Biopharma by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 3,696 shares during the period. Ballentine Partners LLC acquired a new position in Theravance Biopharma in the 3rd quarter worth about $104,000. Hsbc Holdings PLC acquired a new position in Theravance Biopharma during the second quarter worth $108,000. Finally, XTX Topco Ltd acquired a new position in Theravance Biopharma during the second quarter valued at approximately $129,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on TBPH shares. TD Cowen dropped their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Finally, Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $13.75.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.